Direct Oral Anticoagulants or Vitamin K Antagonists after TAVR: Insights from the ENVISAGE-TAVI AF and ATLANTIS Trials

Thromb Haemost. 2023 Mar;123(3):362-365. doi: 10.1055/s-0042-1760128. Epub 2022 Dec 30.
No abstract available

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Stroke* / drug therapy
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Vitamin K

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Vitamin K